Skip to main content
OpenTrials
Completed

NCT Number: NCT02840669

A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)

Friedreich's ataxia (FA) is an autosomal recessive disease with an incidence of 1/50,000 in the Caucasian population. The main manifestations of FA are progressive sensory and cerebellar ataxia and cardiomyopathy (CM). It is the most common form of inherited ataxia. A severe CM affects ~60% of FA patients, mostly young adults, and leads to cardiac failure then death. Currently, no therapy can change the course of this severe cardiomyopathy.

This study is designed to characterize the cardiac manifestations of FA using cardiac magnetic resonance (CMR), echocardiography, serum cardiac biomarkers and evaluation of fatigue severity, in the context of the neurological disease.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Friedreich's Ataxia):

  • Males and females;
  • ≥ 18 years old;
  • Willing and able to provide informed consent;
  • Definitive diagnosis of FA, based on clinical phenotype and genotype;
  • With a hypertrophic cardiomyopathy;
  • Ability to complete study assessments.

Exclusion criteria

(Friedreich's Ataxia):

  • Symptoms of cardiac failure;
  • Moderate to severe atrial or ventricular arrhythmias;
  • History of angina pectoris;
  • Inability to undergo cardiac MRI;
  • Clinical history or evidence of diabetes;
  • Abnormal kidney function;
  • Females who are pregnant or nursing;
  • Receipt of an investigational drug within 30 days or 5 half-lives, or active enrollment in an investigational medication or device study;
  • Inability to sit with back support;
  • Inability to undergo exercise test;
  • Inability to comply with all study requirements;
  • Unaffiliated to any French health insurance or equivalent.

Inclusion criteria

(Healthy Volunteers):

  • Healthy males and females;
  • ≥ 18 years old;
  • Willing and able to provide informed consent;
  • Age and gender matched to the Friedreich's Ataxia group;
  • Ability to complete study assessments.

Exclusion criteria

(Healthy Volunteers):

  • Inability to undergo cardiac MRI;
  • Clinical history or evidence of diabetes;
  • Abnormal kidney function;
  • Females who are pregnant or nursing;
  • Receipt of an investigational drug within 30 days or 5 half-lives, or active enrollment in an investigational medication or device study;
  • Inability to undergo exercise test;
  • Inability to comply with all study requirements;
  • Unaffiliated to any French health insurance or equivalent.

Treatment and study plan

Cardiac magnetic resonance imaging (CMR)

Procedure

Exercise-stress test

Procedure

Echocardiography (ECHO)

Procedure

Cardiac-related blood studies

Procedure

Primary outcomes

  1. Exercise-stress test

    Time frame: 2 hours

  2. Cardiac magnetic resonance imaging (CMR)

    Time frame: 2 hours

  3. Echocardiogram

    Time frame: 2 hours

  4. Level of cardiac biomarkers in serum

    Time frame: 30 minutes

  5. Fatigue Severity Scale

    Time frame: 30 minutes

Sponsors and collaborators

Lead sponsor

Adverum Biotechnologies, Inc.

Industry

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jul 21, 2016
Registry last updated
Dec 10, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.